The delay removes a key near-term catalyst for CPIX. Monitor for future data release dates and any updates on the ifetroban pipeline. The stock may face selling pressure as the market reprices the timeline risk for this DMD program.
Price Chart
Executive Summary
Cumberland Pharmaceuticals disclosed that long-term safety and efficacy data from the open-label extension of its Phase 2 FIGHT DMD trial evaluating ifetroban for Duchenne muscular dystrophy heart disease is not yet available and will no longer be presented in August 2026 as previously expected. The company intends to present the data at a future date. This is a clinical timeline delay that removes a near-term catalyst for the stock, though no negative data or safety signals were reported.
Key Facts
- Cumberland Pharmaceuticals presented Phase 2 FIGHT DMD trial data for ifetroban at the Parent Project Muscular Dystrophy conference on June 26, 2026.
- A slide from that presentation indicated long-term safety and efficacy data from the open-label extension was expected in August 2026.
- The company now states such data is not yet available and it no longer expects to present this data in August 2026.
- The company intends to present the data at a future date when it becomes available.
- No financial figures, revenue, earnings, or guidance were provided in this filing.
Financial Impact
No financial impact disclosed; the filing contains no revenue, earnings, or balance sheet data.
Risk Factors
- Further delays in data availability could erode investor confidence in the ifetroban program.
- No safety or efficacy data was released, leaving the program's ultimate success uncertain.
- The company has a small market cap ($130M) and limited pipeline diversification, making it highly sensitive to clinical setbacks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CPIX) — Batch item 1 | 0001087294-26-000064 |
| Document: 0001087294-26-000064-index.html | 0001087294-26-000064 |
| Document: 0001087294-26-000064.txt | 0001087294-26-000064 |
| 8-K Filing (CPIX) — Batch item 4 | 0001087294-26-000064 |
| Document: 0001087294-26-000064-index.html | 0001087294-26-000064 |
| Document: 0001087294-26-000064.txt | 0001087294-26-000064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $5.22 | awaiting T+1 | — | $4.35 (−16.67%) |
Oct 23, 2026 3d ago | 8-K | $8.46 | awaiting T+1 | — | $4.35 (−48.58%) |
Aug 28, 2026 8w ago | 8-K | $6.69 $6.56 | ▲ +1.94% | ▲ +1.26% | $4.35 (+34.98%) |
Jul 13, 2026 15w ago | Press Release | $6.54 $6.99 | ▲ +6.80% | ▲ +6.45% | $4.35 (−33.49%) |
May 26, 2026 21w ago | DEFM14A | $5.77 $5.86 | ▲ +1.56% | ▲ +1.55% | $4.35 (−24.61%) |
Apr 23, 2026 26w ago | DEFA14A / 8-K | $3.90 $4.06 | ▲ +4.10% | ▲ +3.32% | $4.35 (+11.54%) |
Mar 9, 2026 33w ago | DEFA14A | $3.16 $3.08 | ▼ −2.53% | ▼ −2.43% | $4.35 (+37.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers